Bristol consolidating discovery research on East Coast, closing Seattle site.
Executive Summary
BRISTOL CONSOLIDATES DISCOVERY RESEARCH ON EAST COAST with the closing of its Seattle discovery research operation. Half of the 240 staff members at the Seattle immunology discovery operation will be invited to relocate to Princeton, N.J., Bristol-Myers Squibb announced April 23. The transition is expected to be completed by early 1998. The Seattle site was formerly the home of Oncogen, a joint venture of Syntex and Genetic Systems; Bristol became sole owner of the site in 1986 following its purchase of Genetic Systems.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth